Business Wire

Sodali & Co Announces Executive Leadership Appointments

7.1.2026 17:00:00 CET | Business Wire | Press Release

Share

Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale.

The appointments are as follows:

Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian Financial Review, The Australian, and The Daily Telegraph.

Aneliya Crawford has joined as Chief Partnerships Officer & Global Head of Shareholder Advisory, based in New York. Most recently, Aneliya served as the Head of Corporate Shareholder Advisory, Americas at UBS. Prior to that as Global Head of Activism and Defense at UBS, she built the shareholder activism and defense practice for the investment bank globally. Prior to UBS, Aneliya was an equity partner in the M&A group at Schulte, Roth & Zabel, co-heading one of the leading shareholder activism groups in private law. She was previously an M&A partner at Olshan Frome Wolosky.

Liz Micci has joined as Chief Client Officer & Global Head of Strategic Communications, based in New York. Lizis a proven communications executive with 25 years of experience at leading strategic communications firms. With expertise spanning corporate, crisis, and financial communications, Liz joins from FGS Global, where she held a number of leadership roles, most recently co-leading the firm’s Global Strategy and Reputation Practice and serving on the North America Executive Committee.

Nadia Krivickova has joined as Chief People Officer based in New York and Stamford, CT. Nadia joins Sodali from Forensic Risk Alliance, where she served as Chief People Officer, following nearly 20 years at AlixPartners in New York, where she led Americas People Planning and Operations, Global Strategic Staffing, and other key People roles. Before pivoting her career to HR, Nadia was a consultant in AlixPartners’ Risk Advisory practice, focusing on forensic accounting and corporate investigations.

In addition to Brett, Aneliya, Liz, and Nadia, the following Sodali leaders will sit on the newly formed Executive Leadership Team:

  • Dan Wadleigh, Chief Financial Officer, who joined Sodali in 2025 after holding CFO positions at a variety of communications, advertising, and marketing firms.
  • Amy Murphy, Global Head of Strategy, who joined Sodali from PwC in 2025.
  • Lauren Palumbo, Chief of Staff, who previously served as Head of Operations for Sodali’s Sustainability Practice.

Andrew Benett, Chief Executive Officer of Sodali & Co, commented:

“Companies today face high-stakes decisions where financial health, stakeholder trust, governance risk, and sustainability expectations are all intertwined. At Sodali & Co, we are ideally positioned to help clients navigate these dynamics with an integrated, global approach that is unique in our industry.

The ability to attract and retain world-class talent such as Brett, Aneliya, Liz, and Nadia is both an endorsement of and an accelerant to this specialized strategy. Working together as one team, we will provide our clients with integrated expertise and bespoke advice to address complex interconnected issues, identify and capitalize on strategic opportunities, and drive successful business outcomes.Meanwhile, we will continue to invest in our unmatched capital markets data and intelligence capabilities to provide clients the differentiated insights that underpin our offering.”

These appointments come after a period of sustained growth for Sodali. The firm reported a record year the 12 months to June 30, 2025, as clients face increasingly complicated and interconnected issues including cross border M&A and shareholder activism.

ABOUT SODALI & CO

Sodali & Co is the leading global capital markets-centric stakeholder advisory firm providing a full suite of integrated shareholder, sustainability, and strategic communications advisory services. The Firm delivers clients differentiated insights, integrated expertise, and bespoke advice to address complex interconnected issues, identify and capitalize on strategic opportunities, and drive successful business outcomes. Sodali operates out of three global headquarters in New York, London, and Sydney and is supported by 12 regional offices in major financial capitals around the world. Its work is consistently recognized by leading industry rankings and awards, including being named the #1 Proxy Solicitation Firm in the Diligent Advisor Awards, #1 in Global Activism Solicitor in Bloomberg’s 2025 Activism Review, #1 in APAC & Sovereign Deals Liability Management, Top Recommended Reputation Managers in Spears500, and #4 for FTSE 350 representation in the UK corporate adviser rankings. For more information, please visit www.sodali.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260107521979/en/

Contacts

Press Contacts
Europe:
Victoria Palmer-Moore
vpm@sodali.com
+44 7725 565 545

Australia/APAC:
Jon Snowball
jon.snowball@sodali.com
+61 477 946 068

US:
Liz Micci
elizabeth.micci@sodali.com
+1 347 675 2883

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye